title: Natural killer cell receptor--repertoire and functions after induction therapy by polyclonal rabbit anti-thymocyte globulin in unsensitized kidney transplant recipients.
abstract: Polyclonal rabbit anti-thymocyte globulin (rATG) is widely used in solid organ transplantation (SOT) as induction therapy or to treat corticosteroid-resistant rejection. In vivo, the effect of rATG on natural killer (NK) cells has not been studied. These cells are of particular relevance after SOT because classical immunosuppressive drugs do not inhibit or even can activate NK cells. A cohort of 20 recipients at low immunological risk, that had been receiving rATG as induction therapy, was analyzed for receptor repertoire, cytotoxicity and capacity of NK cells to secrete IFN-γ before kidney transplantation and at different time points thereafter. NK cells expressed fewer killer-cell immunoglobulin-like receptors (KIR), fewer activating receptors NKG2D, but more inhibitory receptor NKG2A compatible with an immature phenotype in the first 6 months post transplantation. Both cytotoxicity of NK cells and the secretion of IFN-γ were preserved over time after transplantation.
authors: Division of Nephrology, Geneva University Hospital and Medical School, Geneva, Switzerland.
authors: Karine
authors: K
authors: Hadaya
authors: Yannick
authors: Y
authors: Avila
authors: Laure
authors: L
authors: Valloton
authors: Casimir
authors: C
authors: de Rham
authors: Cedric
authors: C
authors: Bandelier
authors: Sylvie
authors: S
authors: Ferrari-Lacraz
authors: Manuel
authors: M
authors: Pascual
authors: Giuseppe
authors: G
authors: Pantaleo
authors: Pierre-Yves
authors: PY
authors: Martin
authors: Leo
authors: L
authors: Buhler
authors: Jean
authors: J
authors: Villard
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000961:Antilymphocyte Serum / Q000494:pharmacology* / Q000627:therapeutic use; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D018664:Interleukin-12 / Q000494:pharmacology; D020014:K562 Cells; D016030:Kidney Transplantation / Q000276:immunology*; D007694:Killer Cells, Natural / Q000166:cytology / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism*; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects; D052118:Lysosomal-Associated Membrane Protein 1 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D055654:NK Cell Lectin-Like Receptor Subfamily C / Q000378:metabolism; D011817:Rabbits; D054340:Receptors, KIR / Q000378:metabolism; D055636:Receptors, Natural Cytotoxicity Triggering / Q000378:metabolism; D055607:Receptors, Natural Killer Cell / Q000378:metabolism*; D055815:Young Adult
chemical_list: D000961:Antilymphocyte Serum; D052118:Lysosomal-Associated Membrane Protein 1; D055654:NK Cell Lectin-Like Receptor Subfamily C; D054340:Receptors, KIR; D055636:Receptors, Natural Cytotoxicity Triggering; D055607:Receptors, Natural Killer Cell; D018664:Interleukin-12; D007371:Interferon-gamma